{"protocolSection":{"identificationModule":{"nctId":"NCT06470841","orgStudyIdInfo":{"id":"WATCH2023"},"organization":{"fullName":"Navy General Hospital, Beijing","class":"OTHER"},"briefTitle":"CHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML","officialTitle":"CHG Regimen Combined With Venetoclax and Azacytidine in Newly Diagnosed Acute Myeloid Leukemia"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-07-30","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2027-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-17","studyFirstSubmitQcDate":"2024-06-17","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-17","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Liren Qian","investigatorTitle":"Vice Director","investigatorAffiliation":"Navy General Hospital, Beijing"},"leadSponsor":{"name":"Navy General Hospital, Beijing","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this phase 2 trial is to test the safety and efficacy of CHG Combined With Venetoclax in treating patients with newly diagnosed AML.","detailedDescription":"The investigators will evaluate response rate of CHG regimen Combined With Venetoclax in newly diagnosed acute myeloid leukemia. After induction therapy, patients will be given standardized treatment according to risk stratification according to NCCN guidelines. Progression free survival (PFS), Overall survival (OS), and Toxicity will be counted."},"conditionsModule":{"conditions":["Acute Myeloid Leukemia"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":85,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"CHG Combined With Venetoclax and Azacytidine","type":"EXPERIMENTAL","description":"Patients were treated by CHG Combined With Venetoclax and Azacytidine","interventionNames":["Drug: CHG Combined With Venetoclax and Azacytidine"]}],"interventions":[{"type":"DRUG","name":"CHG Combined With Venetoclax and Azacytidine","description":"Patients were treated by CHG Combined With Venetoclax and Azacytidine:\n\nVenetoclax 100mg po qd d1, 200mg po qd d2, 400mg po qd d3-14; Azacytidine 75 mg/m2 subcutaneous injection qd d1-7; Homoharringtonine 1mg/m2 iv qd d1-14; Cytarabine 10mg/m2 subcutaneous injection q12h d1-14; G 250ug/m2 subcutaneous injection qd d0-14.","armGroupLabels":["CHG Combined With Venetoclax and Azacytidine"],"otherNames":["VACHG"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Overall Response Rate (ORR)","description":"ORR was defined as the proportion of patients who achieved CR or PR as their best response","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS was defined as time from diagnosis to death from any cause or the last follow-up","timeFrame":"through study completion, an average of 3 years"},{"measure":"Progression Free Survival (PFS)","description":"For patients in morphologic remission, documented relapse was considered progression. Relapse following complete remission(CR) is defined as reappearance of leukemic blasts in the peripheral blood or the finding of more than 5% blasts in the BM, not attributable to another cause (eg, BM regeneration after consolidation therapy) or extramedullary relapse.","timeFrame":"2 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The patient should, in the investigator's opinion, be able to meet all clinical trial requirements.\n* The patient is willing and able to adhere to the study visit schedule and other protocol requirements.\n* The patient should be diagnosed with AML according to the standard criteria of the World Health Organisation (WHO).\n* The patient should not have received any prior treatment for AML.\n\nExclusion Criteria:\n\n* Active or uncontrolled infections requiring systemic treatment within 14 days before enrollment.\n* Any instability of systemic disease, including but not limited to severe cardiac, liver, kidney, or metabolic disease need therapy.\n* Pregnant or lactating women.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Liren Qian, PhD","role":"CONTACT","phone":"+861066947192","email":"qlr2007@126.com"}],"overallOfficials":[{"name":"Liren Qian, PhD","affiliation":"Navy General Hospital, Beijing","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Navy General Hospital","city":"Beijing","state":"Beijing","zip":"100048","country":"China","contacts":[{"name":"Liren Qian, M.D.","role":"CONTACT","phone":"+861066957676","email":"qlr2007@126.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000007938","term":"Leukemia"},{"id":"D000007951","term":"Leukemia, Myeloid"},{"id":"D000015470","term":"Leukemia, Myeloid, Acute"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000006402","term":"Hematologic Diseases"}],"browseLeaves":[{"id":"M10945","name":"Leukemia","asFound":"Leukemia","relevance":"HIGH"},{"id":"M10955","name":"Leukemia, Myeloid","asFound":"Myeloid Leukemia","relevance":"HIGH"},{"id":"M18127","name":"Leukemia, Myeloid, Acute","asFound":"Acute Myeloid Leukemia","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M9490","name":"Hematologic Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"},{"id":"T182","name":"Acute Myeloid Leukemia","asFound":"Acute Myeloid Leukemia","relevance":"HIGH"},{"id":"T3995","name":"Myeloid Leukemia","asFound":"Myeloid Leukemia","relevance":"HIGH"},{"id":"T188","name":"Acute Non Lymphoblastic Leukemia","asFound":"Acute Myeloid Leukemia","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001374","term":"Azacitidine"},{"id":"C000579720","term":"Venetoclax"}],"ancestors":[{"id":"D000000964","term":"Antimetabolites, Antineoplastic"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000970","term":"Antineoplastic Agents"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M249656","name":"Venetoclax","asFound":"Stage III","relevance":"HIGH"},{"id":"M6766","name":"Cytarabine","relevance":"LOW"},{"id":"M4673","name":"Azacitidine","asFound":"Resistance","relevance":"HIGH"},{"id":"M1920","name":"Homoharringtonine","relevance":"LOW"},{"id":"M4281","name":"Antimetabolites","relevance":"LOW"},{"id":"M7951","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"ANeo","name":"Antineoplastic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"}]}},"hasResults":false}